Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation

Trial Profile

Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms XaMINA
  • Sponsors Bayer
  • Most Recent Events

    • 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Sep 2018 Planned End Date changed from 31 Dec 2019 to 31 Oct 2019.
    • 24 Sep 2018 Planned primary completion date changed from 30 Sep 2019 to 31 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top